Cargando…
Dysuria Following Stereotactic Body Radiation Therapy for Prostate Cancer
BACKGROUND: Dysuria following prostate radiation therapy is a common toxicity that adversely affects patients’ quality of life and may be difficult to manage. METHODS: Two hundred four patients treated with stereotactic body radiation therapy (SBRT) from 2007 to 2010 for localized prostate carcinoma...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4490223/ https://www.ncbi.nlm.nih.gov/pubmed/26191507 http://dx.doi.org/10.3389/fonc.2015.00151 |
_version_ | 1782379466374250496 |
---|---|
author | Janowski, Einsley-Marie Kole, Thomas P. Chen, Leonard N. Kim, Joy S. Yung, Thomas M. Collins, Brian Timothy Suy, Simeng Lynch, John H. Dritschilo, Anatoly Collins, Sean P. |
author_facet | Janowski, Einsley-Marie Kole, Thomas P. Chen, Leonard N. Kim, Joy S. Yung, Thomas M. Collins, Brian Timothy Suy, Simeng Lynch, John H. Dritschilo, Anatoly Collins, Sean P. |
author_sort | Janowski, Einsley-Marie |
collection | PubMed |
description | BACKGROUND: Dysuria following prostate radiation therapy is a common toxicity that adversely affects patients’ quality of life and may be difficult to manage. METHODS: Two hundred four patients treated with stereotactic body radiation therapy (SBRT) from 2007 to 2010 for localized prostate carcinoma with a minimum follow-up of 3 years were included in this retrospective review of prospectively collected data. All patients were treated to 35–36.25 Gy in five fractions delivered with robotic SBRT with real time fiducial tracking. Dysuria and other lower urinary tract symptoms were assessed via Question 4b (Pain or burning on urination) of the expanded prostate index composite-26 and the American Urological Association (AUA) Symptom Score at baseline and at routine follow-up. RESULTS: Two hundred four patients (82 low-, 105 intermediate-, and 17 high-risk according to the D’Amico classification) at a median age of 69 years (range 48–91) received SBRT for their localized prostate cancer with a median follow-up of 47 months. Bother associated with dysuria significantly increased from a baseline of 12% to a maximum of 43% at 1 month (p < 0.0001). There were two distinct peaks of moderate to severe dysuria bother at 1 month and at 6–12 months, with 9% of patients experiencing a late transient dysuria flare. While a low level of dysuria was seen through the first 2 years of follow-up, it returned to below baseline by 2 years (p = 0.91). The median baseline AUA score of 7.5 significantly increased to 11 at 1 month (p < 0.0001) and returned to 7 at 3 months (p = 0.54). Patients with dysuria had a statistically higher AUA score at baseline and at all follow-ups up to 30 months. Dysuria significantly correlated with dose and AUA score on multivariate analysis. Frequency and strain significantly correlated with dysuria on stepwise multivariate analysis. CONCLUSION: The rate and severity of dysuria following SBRT is comparable to patients treated with other radiation modalities. |
format | Online Article Text |
id | pubmed-4490223 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-44902232015-07-17 Dysuria Following Stereotactic Body Radiation Therapy for Prostate Cancer Janowski, Einsley-Marie Kole, Thomas P. Chen, Leonard N. Kim, Joy S. Yung, Thomas M. Collins, Brian Timothy Suy, Simeng Lynch, John H. Dritschilo, Anatoly Collins, Sean P. Front Oncol Oncology BACKGROUND: Dysuria following prostate radiation therapy is a common toxicity that adversely affects patients’ quality of life and may be difficult to manage. METHODS: Two hundred four patients treated with stereotactic body radiation therapy (SBRT) from 2007 to 2010 for localized prostate carcinoma with a minimum follow-up of 3 years were included in this retrospective review of prospectively collected data. All patients were treated to 35–36.25 Gy in five fractions delivered with robotic SBRT with real time fiducial tracking. Dysuria and other lower urinary tract symptoms were assessed via Question 4b (Pain or burning on urination) of the expanded prostate index composite-26 and the American Urological Association (AUA) Symptom Score at baseline and at routine follow-up. RESULTS: Two hundred four patients (82 low-, 105 intermediate-, and 17 high-risk according to the D’Amico classification) at a median age of 69 years (range 48–91) received SBRT for their localized prostate cancer with a median follow-up of 47 months. Bother associated with dysuria significantly increased from a baseline of 12% to a maximum of 43% at 1 month (p < 0.0001). There were two distinct peaks of moderate to severe dysuria bother at 1 month and at 6–12 months, with 9% of patients experiencing a late transient dysuria flare. While a low level of dysuria was seen through the first 2 years of follow-up, it returned to below baseline by 2 years (p = 0.91). The median baseline AUA score of 7.5 significantly increased to 11 at 1 month (p < 0.0001) and returned to 7 at 3 months (p = 0.54). Patients with dysuria had a statistically higher AUA score at baseline and at all follow-ups up to 30 months. Dysuria significantly correlated with dose and AUA score on multivariate analysis. Frequency and strain significantly correlated with dysuria on stepwise multivariate analysis. CONCLUSION: The rate and severity of dysuria following SBRT is comparable to patients treated with other radiation modalities. Frontiers Media S.A. 2015-07-03 /pmc/articles/PMC4490223/ /pubmed/26191507 http://dx.doi.org/10.3389/fonc.2015.00151 Text en Copyright © 2015 Janowski, Kole, Chen, Kim, Yung, Collins, Suy, Lynch, Dritschilo and Collins. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Janowski, Einsley-Marie Kole, Thomas P. Chen, Leonard N. Kim, Joy S. Yung, Thomas M. Collins, Brian Timothy Suy, Simeng Lynch, John H. Dritschilo, Anatoly Collins, Sean P. Dysuria Following Stereotactic Body Radiation Therapy for Prostate Cancer |
title | Dysuria Following Stereotactic Body Radiation Therapy for Prostate Cancer |
title_full | Dysuria Following Stereotactic Body Radiation Therapy for Prostate Cancer |
title_fullStr | Dysuria Following Stereotactic Body Radiation Therapy for Prostate Cancer |
title_full_unstemmed | Dysuria Following Stereotactic Body Radiation Therapy for Prostate Cancer |
title_short | Dysuria Following Stereotactic Body Radiation Therapy for Prostate Cancer |
title_sort | dysuria following stereotactic body radiation therapy for prostate cancer |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4490223/ https://www.ncbi.nlm.nih.gov/pubmed/26191507 http://dx.doi.org/10.3389/fonc.2015.00151 |
work_keys_str_mv | AT janowskieinsleymarie dysuriafollowingstereotacticbodyradiationtherapyforprostatecancer AT kolethomasp dysuriafollowingstereotacticbodyradiationtherapyforprostatecancer AT chenleonardn dysuriafollowingstereotacticbodyradiationtherapyforprostatecancer AT kimjoys dysuriafollowingstereotacticbodyradiationtherapyforprostatecancer AT yungthomasm dysuriafollowingstereotacticbodyradiationtherapyforprostatecancer AT collinsbriantimothy dysuriafollowingstereotacticbodyradiationtherapyforprostatecancer AT suysimeng dysuriafollowingstereotacticbodyradiationtherapyforprostatecancer AT lynchjohnh dysuriafollowingstereotacticbodyradiationtherapyforprostatecancer AT dritschiloanatoly dysuriafollowingstereotacticbodyradiationtherapyforprostatecancer AT collinsseanp dysuriafollowingstereotacticbodyradiationtherapyforprostatecancer |